Shares of Certara, Inc. (CERT) are soaring 5.43% in intraday trading, following BMO Capital's initiation of coverage on the stock. The surge in share price comes as investors react positively to the new analyst attention on the biosimulation software company.

BMO Capital has initiated coverage on Certara with a Market Perform rating and a price target of $9. This new coverage appears to have sparked investor interest, driving up the stock price. The $9 price target suggests potential upside from the stock's previous closing price, which may be contributing to the positive sentiment.

It's worth noting that Certara currently has an average rating of overweight from analysts polled by FactSet, with a mean price target of $13.50. This indicates that overall, analysts have a positive outlook on the stock, with BMO Capital's new coverage adding to the existing analyst sentiment. The market's strong reaction to this new coverage underscores the importance of analyst opinions in shaping investor perceptions and driving stock movements.